12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (453 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-08-14. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: boneplacebocordeffectscompletion of
  Phrases that lowered it: diseasesparticipantsopen labelinvestigatesingle
• Sponsor's past termination rate: 19.7% (raises risk) · Sponsor's track record
• Minimum age: 21 (lowers risk) · Who can join
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports with a death: 9.0% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 87 (lowers risk) · Sponsor's track record
• Sponsor's past trials: 213 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Design: single group (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports marked serious: 73.9% (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 36258 (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Keywords listed: 15 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 6261 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury NCT01225055 · started 2010 · scored riskier than 35% of active trials completed
• Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide NCT02195895 · started 2014 · scored riskier than 59% of active trials completed
• A Study for the Transdermal Application of Teriparatide NCT01011556 · started 2009 · scored riskier than 21% of active trials completed
• Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI NCT04232657 · started 2021 · scored riskier than 34% of active trials completed
• Pharmacokinetic and PHarmacodynamic Analysis and Evaluation of Teriparatide (PTH 1-34) Between Sexes NCT04921124 · started 2021 · scored riskier than 5% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.